Assoc. Prof. Li, Hoi Yeung
Dr. Li Hoi Yeung’s research integrates cancer biology, drug discovery from natural compounds, and advanced microscopy imaging. He specializes in developing targeted cancer therapies through synthetic lethality mechanisms using bioactive natural products. His innovative use of AI-driven platforms, exemplified by the patented Drug-Target Interaction Graph Neural Network, significantly accelerates therapeutic discovery. Dr. Li has attracted substantial industrial funding and established multiple successful collaborations with biotech companies, translating laboratory innovations into potential medical solutions. His entrepreneurial achievements include founding NYB-AI, an AI-focused drug discovery startup selected by the Nvidia Ignition AI program. With over 50 peer-reviewed publications and multiple patents, Dr. Li demonstrates a sustained commitment to bridging academia and industry, significantly advancing translational biomedical research and innovation.
Patent
Research Areas
Principal Research Scientist
PhD Student
Project Officer
- Wong, C.H., Chan, H., Ho, C.Y., Lai, S.K., Chan, K.S.K., Koh, C.G., and Li, H.Y. "Apoptotic histone modification inhibits the nuclear transport by regulating RCC1." Nature Cell Biology 11 (2009): 36–45. https://doi.org/10.1038/ncb1810
- Lai, S.K., Wong, C.H., Lee, Y.P., and Li, H.Y. "Caspase-3-mediated degradation of condensin Cap-H regulates mitotic cell death." Cell Death and Differentiation 18, no. 6 (2011): 996–1004. https://doi.org/10.1038/cdd.2010.165
- Chan, K.S., Koh, C.G., and Li, H.Y. "Mitosis-targeted anti-cancer therapies: where they stand." Cell Death and Disease 3 (2012): e411. https://doi.org/10.1038/cddis.2012.148
- Khong, N.Z.J., Lai, S.K., Zeng, Y., Koh, C.G., Liang, Z.X., Chiam, K.H., and Li, H.Y. "Dynamic swimming patterns of Pseudomonas aeruginosa near a vertical wall during initial attachment stages of biofilm formation." Scientific Reports 11 (2021): 1952. https://doi.org/10.1038/s41598-021-81621-w